Cardiovascular and Renal Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Clicks: 1
ID: 313356
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #45 of 71 articles by views in european heart journal - quality of care and clinical outcomes
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a foundational therapeutic option for type 2 diabetes mellitus (T2DM), offering glycemic control and cardiovascular benefits. This systematic review and meta-analysis evaluates the impact of GLP-1RAs on cardiovascular outcomes in patients with T2DM. Methods We conducted a comprehensive search of PubMed, Embase, and Cochrane Library up to March 31, 2025, for randomized controlled trials (RCTs) comparing GLP-1RAs with placebo in T2DM patients. Risk ratios (RR) with 95% confidence intervals (CIs) were pooled using a random-effects model. Results Twenty RCTs involving 83,004 patients were included. GLP-1RAs significantly reduced the risk of major adverse cardiovascular events (RR 0.87, 95% CI 0.83–0.92), all-cause death (RR 0.89, 95% CI 0.84–0.93), cardiovascular death (RR 0.88, 95% CI 0.81–0.94), myocardial infarction (RR 0.87, 95% CI 0.79–0.96), stroke (RR 0.88, 95% CI 0.81–0.96) and composite renal outcome (RR 0.80, 95% CI 0.73–0.88) compared to placebo. In addition, a trend of reduction in heart failure hospitalizations (RR 0.93, 95% CI 0.85–1.01), and coronary revascularization (RR = 0.87, 95% CI 0.74 to 1.01) was observed with GLP-1 RAs without reaching statistical significance. Conclusion GLP-1RAs are associated with improved cardiovascular outcomes in patients with T2DM. These findings support current guideline recommendations and highlight their cardioprotective benefits beyond glycemic control in patients with T2DM.
| Reference Key |
openalex_W7161376369
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | M Ahmed, Tallal Mushtaq Hashmi, Maryam Shahzad, Rohma Zia, Hadiah Ashraf, Raheel Ahmed, Muhammad Rashid, Stephen J Greene, Robert J Mentz, Marat Fudim, Gregg C Fonarow, Jamal S Rana |
| Journal | european heart journal - quality of care and clinical outcomes |
| Year | 2026 |
| DOI |
10.1093/ehjqcco/qcag079
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.